Published in Am J Gastroenterol on December 14, 2010
Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med (2013) 1.71
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.57
Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.03
Vaccines and recommendations for their use in inflammatory bowel disease. World J Gastroenterol (2013) 0.93
Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis (2013) 0.88
HFcRn-mediated transplacental immunoglobulin G transport: protection of and threat to the human fetus and newborn. Wien Med Wochenschr (2012) 0.87
Inflammatory bowel diseases and human reproduction: a comprehensive evidence-based review. World J Gastroenterol (2014) 0.85
Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives. BMJ Open (2014) 0.84
Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol (2013) 0.83
Editorial: consensus guidelines: method or madness? Am J Gastroenterol (2011) 0.82
Impact of mode of delivery on outcomes in patients with perianal Crohn's disease. Inflamm Bowel Dis (2014) 0.81
From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol (2015) 0.80
Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. Can J Gastroenterol Hepatol (2014) 0.80
Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease. Expert Opin Drug Saf (2012) 0.79
The Effect of Maternal Peripartum Anti-TNFα Use on Infant Immune Response. Dig Dis Sci (2016) 0.78
Mode of childbirth and long-term outcomes in women with inflammatory bowel diseases. Dig Dis Sci (2014) 0.78
From conception to delivery: managing the pregnant inflammatory bowel disease patient. World J Gastroenterol (2014) 0.78
IBD: Can TNF inhibitors be administered during the third trimester? Nat Rev Gastroenterol Hepatol (2012) 0.77
A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol (2015) 0.77
Current issues in pediatric inflammatory bowel disease-associated arthropathies. World J Gastroenterol (2014) 0.75
Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding. Transl Vis Sci Technol (2012) 0.75
Treatment of pregnant women with a diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther (2016) 0.75
Pregnancy Concerns in Women With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) (2015) 0.75
Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education. Can J Gastroenterol Hepatol (2016) 0.75
A 29-year-old woman with Crohn disease considering pregnancy. CMAJ (2015) 0.75
[Guidelines for vaccination of immunocompromised individuals]. Wien Klin Wochenschr (2016) 0.75
Managing Crohn's Disease during Pregnancy. Maedica (Buchar) (2016) 0.75
Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up. Dig Dis Sci (2017) 0.75
Management of Inflammatory Bowel Disease During Pregnancy. Dig Dis Sci (2016) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93
Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 7.81
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology (2006) 5.73
Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut (2011) 4.79
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Crohn's disease. Lancet (2012) 4.42
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Management of Crohn's disease in adults. Am J Gastroenterol (2009) 3.94
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis (2010) 3.55
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Ulcerative colitis. Lancet (2012) 3.38
Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet (2008) 3.36
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol (2008) 3.30
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09
Mucosal healing in inflammatory bowel diseases: a systematic review. Gut (2012) 3.02
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol (2012) 2.88
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut (2010) 2.82
Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol (2009) 2.80
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78
Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology (2007) 2.76
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med (2011) 2.74
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol (2009) 2.70
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol (2010) 2.55
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol (2008) 2.41
Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest (2014) 2.39
Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am (2002) 2.37
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology (2006) 2.34
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol (2013) 2.31
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30
Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol (2006) 2.24
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol (2008) 2.15
A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis (2014) 2.09
The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology (2013) 2.04
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut (2013) 2.03
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol (2006) 2.03
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology (2012) 2.03
Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis (2007) 1.97
Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg (2007) 1.97
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut (2006) 1.97
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol (2002) 1.89
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol (2003) 1.86
Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol (2009) 1.86
Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm Bowel Dis (2007) 1.85
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol (2010) 1.82
World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis (2010) 1.82
Chronic abdominal pain in children: a clinical report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr (2005) 1.81
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology (2002) 1.80
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol (2012) 1.80
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr (2014) 1.78
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology (2008) 1.78
Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis (2010) 1.78
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr (2007) 1.74
Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis (2012) 1.73
TUCAN (CARD8) genetic variants and inflammatory bowel disease. Gastroenterology (2006) 1.73
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol (2007) 1.72
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol (2008) 1.70
Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol (2004) 1.69
Weight loss at high altitude: pathophysiology and practical implications. Eur J Gastroenterol Hepatol (2006) 1.68
A common CTLA4 haplotype associated with coeliac disease. Eur J Hum Genet (2005) 1.65
Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study. Radiology (2003) 1.63
Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials (2007) 1.62
Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology (2006) 1.60
Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol (2003) 1.60
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology (2007) 1.60
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol (2005) 1.59
Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg (2010) 1.54
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology (2010) 1.54
Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol (2010) 1.54
Are activated T cells regulators of bone metabolism in children with Crohn disease? J Pediatr (2006) 1.54
Microscopic colitis: a review. Am J Gastroenterol (2002) 1.53
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology (2008) 1.53
Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr (2012) 1.52
Advances in the treatment of Crohn's disease. Gastroenterology (2004) 1.51
Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology (2006) 1.51
Chronic Abdominal Pain In Children: a Technical Report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr (2005) 1.51
Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. Eur J Clin Pharmacol (2009) 1.50
Small intestine contrast ultrasonography in pediatric Crohn's disease. J Pediatr (2013) 1.49
Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2006) 1.49
Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol (2011) 1.49